Amit Sachdev - 24 Feb 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
24 Feb 2026
Net transactions value
-$1,634,199
Form type
4
Filing time
26 Feb 2026, 18:50:47 UTC
Previous filing
23 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sachdev Amit EVP Chief Patient & Ext Af Off C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON /s/ Christiana Stevenson, Attorney-in-Fact 26 Feb 2026 0001406338

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $736,397 -1,518 -2.6% $485.11 57,416 24 Feb 2026 Direct
transaction VRTX Common Stock Sale $897,802 -1,846 -3.2% $486.35 55,570 25 Feb 2026 Direct F1
holding VRTX Common Stock 882 24 Feb 2026 401(k)
holding VRTX Common Stock 9,301 24 Feb 2026 Held in Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025.